Skip to main content
Premium Trial:

Request an Annual Quote

Activiomics Raises $800K in Funding

Premium

Biotech firm Activiomics this week said it has raised £500,000 ($806,715) in a funding round led by IP Group and joined by IP Venture Fund and members of Activiomics' management team.

The investment, which is about $200,000 short of the $1 million CEO Mark Warne in December told ProteoMonitor the company hoped to raise (PM 12/10/2010), will be used to further grow partnerships with pharma and biotech companies as well as to pursue identification of prognostic and diagnostic protein biomarkers for cancer, the company said.

Activiomics' main technology platform is its TIQUAS, or targeted in-depth quantification of cell signaling, system – a label-free, LC-MS/MS-based approach to quantifying levels of phosphorylated proteins in material like cells or human tissue. The company's proprietary Pescal software enables researchers to quantify identified peptides by automatically extracting their elution profiles and generating extracted ion chromatograms for each.

Since launching in February 2010, the firm has announced two pharma deals – a project for GlaxoSmithKline investigating phosphorylation patterns related to inflammatory stimulus and steroid treatment (PM 04/23/2010), and an agreement with biopharma firm UCB to study cell signaling pathways targeted by therapeutic antibodies.

In December, Warne said the company was negotiating other agreements for cell signaling analysis work, including one with a large biopharma company that it hoped to announce early this year, but as of yet no additional announcements have been made.

In addition to doing fee-for-service work, Activiomics is also pursuing its own internal protein biomarker studies with the ultimate aim of developing proprietary diagnostics.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.